SCHEMBL5894955

SCHEMBL5894955

O=C(O)/C(=C/c1ccc(-c2c(Cl)cc(C(F)(F)F)cc2Cl)o1)NC(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.48
▸ KDM4E B2RXH2 6/20 0.48
▸ GAA P10253 4/20 0.48
▸ POLB P06746 3/20 0.48
▸ HPGD P15428 1/20 0.48
▸ MAPK1 P28482 7/20 0.46
▸ ALDH1A1 P00352 7/20 0.46
▸ MITF O75030 3/20 0.46
▸ HTT P42858 2/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ LMNA P02545 5/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ MEN1 O00255 4/20 0.43
▸ KMT2A Q03164 4/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ P2RX1 P51575 1/20 0.40
▸ RAD52 P43351 1/20 0.39
▸ TP53 P04637 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5894974 1.00 MAPT (0.48) MAPTKDM4EGAAPOLBHPGD
SCHEMBL5894963 1.00 MAPT (0.48) MAPTKDM4EGAAPOLBHPGD
SCHEMBL5896596 0.89 MAPT (0.56) MAPTKDM4EGAAPOLBHPGD
SCHEMBL5896580 0.89 MAPT (0.56) MAPTKDM4EGAAPOLBHPGD
SCHEMBL5896589 0.89 MAPT (0.56) MAPTKDM4EGAAPOLBHPGD
SCHEMBL5897297 0.87 MAPT (0.58) MAPTKDM4EGAAPOLBHPGD
SCHEMBL5897295 0.87 MAPT (0.58) MAPTKDM4EGAAPOLBHPGD
SCHEMBL5897288 0.87 MAPT (0.58) MAPTKDM4EGAAPOLBHPGD
SCHEMBL5896958 0.84 MAPT (0.56) MAPTKDM4EGAAPOLBHPGD
SCHEMBL5896954 0.84 MAPT (0.56) MAPTKDM4EGAAPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7041690-B2 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC (US) 2006-05-09 — — US disclosed
US-20060004063-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC 2006-01-05 — — US disclosed
EP-1532128-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-05-25 — — EP disclosed
US-20040142980-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY 2004-07-22 — — US disclosed
WO-2004002977-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY LLC (US) 2004-01-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142980-A1 Inhibitors of HCV NS5B polymerase POLRMT, POLR1E, CTDSP1 MAPT 3583/4885KDM4E 2739/4885GAA 279/4885
US-20060004063-A1 Inhibitors of HCV NS5B polymerase POLRMT, EIF5B, POLI MAPT 3589/4885KDM4E 2538/4885GAA 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback